A recent study utilized intranasal insulin, delivered via a device, to examine its uptake in brain regions critical to memory and cognition among older adults. Sixteen participants, divided into cognitively normal adults and those with mild cognitive impairment (MCI), showed distinct patterns of insulin distribution. The research, conducted by Kiran K. Solingapuram Sai and colleagues, suggests that intranasal insulin could be a safe method for brain-targeted therapies in Alzheimer's disease. Significant differences in uptake were observed between the cognitively normal and MCI groups, potentially guiding future clinical trials.

Source: Alzheimer's & Dementia